In a patient with ARVD, combination therapy with mexiletine and disopyramide partially suppressed VT attacks but did not modify the prominent late potential, suggesting the late potential itself may not be directly related to the induction of VT attacks.
Answers are grounded in this paper and cite their sources.
May support symptomatic VT control with mexiletine-disopyramide in ARVD; hypothesis-generating on late potential dissociation from arrhythmia.
A case of arrhythmogenic right ventricular dysplasia with frequent episodes of ventricular tachycardia (VT) in a 57-year-old man is reported. His electrocardiogram showed a normal axis and inverted T waves in V1-V3 during sinus rhythm and a left bundle branch block pattern during VT. The VT could be terminated by either intravenous administration of lidocaine or procainamide or by cardioversion. Echocardiogram and right ventriculography showed reduced wall motion of the apex and infundibulum of the dilated right ventricle. No evidence of ischemic heart disease was found by left ventriculography, coronary arteriography and RI scintigraphy. A prominent late potential following the QRS complex was recorded by averaging and magnifying the surface electrocardiogram. The combination of oral mexiletine and disopyramide partially suppressed the VT attacks and relieved the subjective symptoms, however the late potential remained almost unchanged.
No takes yet. Share an insight, caveat, or question.
Saikawa et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: